Bcl-2 expression has been shown in hematopoietic progenitor cells. Through the use of Bcl-2 specific antisense oligonucleotides we herein report the biologic importance of Bcl-2 expression in primary human CD34+ hematopoietic progenitor cells committed to the myeloid lineage. In bone marrow or peripheral blood derived CD34+ cells &I-2 specific antisense decreased cell survival and inhibited the outgrowth of mixed myeloid colonies. A short-term overnight pretreatment of CD34+ cells with 25 pmollL of Bcl-2 antisense in liquid culture completely ablated the growth of granulocyte-macrophage colony-forming cells (GM-CFC) in a subsequent 14 days methylcellulose colony assay. Control experiments using corresponding Bcl-2 sense or nonsense oligonudeotides did not significantly impair cell survival or growth of GM-colony-forming unit. Western blot analyses revealed the Bcl-2 antisense dependent inhibition of expression of the Bcl-2 protein in CD34+ progenitor cells. Furthermore, regulation of Bcl-2 ex-CL-2 IS AN intracellular 26-kD protein anchored to
B the inner mitochondrial membranes, membranes of the smooth endoplasmic reticulum as well as to perinuclear membranes with the bulk of the protein oriented towards the cytosol.'.' Bcl-2 has been proposed to be an intracellular antioxidant protein which serves to neutralize toxic radicals within a cell and thus inhibits processes of programmed cell death.3.4*5 Proteins that share sequence homology to the Bcl-2 oncogene have been identified and a whole family of Bcl-2 homologues is now evolving all serving positive or negative regulatory functions during programmed cell death.6.7.8 Bcl-2 dimerizes with several members of the Bcl-2 family of proteins thereby shifting the ratio of death promoting or death inhibiting forces within a ce11.6.8-1' Multiple studies have shown a key role of the Bcl-2 protein during lymphopoietic development of T lymphocytes as well as B lymphocytes.'2-'6 Aberrant upregulation of Bcl-2 protein expression occurs in follicular lymphomas through the t( 14; 18) (q32;q21) translocation. This rearrangement juxtaposes the Bcl-2 locus to the JH region of the Ig heavy chain and results in the production of high levels of normal Bcl-2 transcripts, which seem to be an important factor of transformation in the development of immunoblastic lymphomas.IS Furthermore, cellular infection of B lymphocytes with Epstein-Barr virus results in the upregulation of Bcl-2 expre~sion.'~ Gain of function experiments showed that a constant upregulation of Bcl-2 expression as a transgene results in prolonged survival of differentiated B lymphocytes and in the development of immunoblastic lymphomas in vivo. 18 Regulation of apoptotic death in normal cells of the lymphoid compartment as well as on different stages during hematopoietic development has been shown to occur at least in part through cytokines like interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), stem cell factor (SCF), and erythropoietin ( E~O ) . *~'~~~~ Specific regions within the IL-3 and GM-CSF receptor's intracellular domains have been identified which are important for the upregulation of Bcl-2 expression in lymphoid cells: Furthermore, promoter analyses identified regulatory elements within the Bcl-2 promoters that are involved in positive or negative regulation of the expression pression by various cytokines including interleukin-10 (IL-10) was studied. 11-Io's effects on the formation of mixed myeloid colonies were examined in the absence or presence of Bd-2 specific antisense. In the absence of Bcl-2 antisense IL-10 significantly extended the colony forming potential of mixed myeloid colonies to 14 days. In the presence of Bcl-2 antisense rhlL-10 completely restored GM-CSF driven colony growth. Fluorescent microscopy, Western blot analysis, and reverse transcriptase-polymerase chain reaction revealed the 11-10 dependent increase in cellular expression of Bcl-2 protein and Bcl-2 mRNA transcripts in CD34+ cells. Thus these results show that Bcl-2 expression is necessary for the formation of GM-CSF-dependent colony growth in vitro and that rhlL-10 increases &I-2 expression and survival in primary human CD34+ hematopoietic progenitor cells that are committed to the myeloid lineage. 0 1996 by The American Society of Hematology.
of the Bcl-2 protein.23 Although the expression and functional importance of the Bcl-2 protein have been studied in great detail during lymphopoiesis, comparatively little data exist with regard to the Bcl-2 expression during regular hematopoiesis. However, the maintenance of cell homeostasis during hematopoietic differentiation not only requires cell activation and proliferation but also differentiation and cellular death.*'.** Bcl-2 expression is found in hematopoietic lineages that are derived from a renewing stem cell like normal myeloid progenitor cells.',24 In cultured myeloblastic cell lines and primary acute myeloid leukemia (AML) cells exposure to Bcl-2 antisense oligonucleotides decreases cell survival as well as the number of clonogenic cells in culture when cells are exposed to high doses of Bcl-2 antisense oligonucleotides for 6 to 15 days in vitro.2s To study the role of the Bcl-2 protein for the outgrowth of mixed myeloid colonies from primary human progenitor cells we performed antisense experiments to block Bcl-2 expression. We used a short-term incubation protocol of primary human hematopoietic CD34+ cells with Bcl-2 specific antisense oligonucleotides for 20 hours in liquid culture. We then investigated the effects of Bcl-2 antisense on cell survival and on the outgrowth of mixed myeloid GM-CSF induced colony growth in vitro in a 14 day methylcellulose colony assay. Most interestingly we found that the immunomodulatory cytokine IL-IO effects Bcl-2 expression in early hematopoietic progenitor cells. In splenic B lymphocytes IL-IO upregulates expression of Bcl-2 and thus increases the survival of these cells in vitro.20 IL-IO has been described as an immunomodulatory cytokine mainly produced by TH2 and B lymphocytes as well as macrophages, keratinocytes, and ovarian cancer cells.2h IL-IO exerts its effects through binding to a specific receptor expressed in low numbers on cells of lymphoid and myeloid origin." IL-IO mainly functions as an antiinflammatory cytokine through the downregulation of interferon-y (IFN-y), TNF-a, IL-I, IL-6, and GM-CSF in cells of the lymphoid compartment." Although IL-IO expression occurs in cells that are isolated from normal human bone marrow (BM) little data exist so far that would explain a functional role of IL-IO in the developmental process of hematopoietic cells. The results of the study presented here provide evidence ( I ) that BcI-2 expression is important for the formation of mixed myeloid colonies in vitro, (2) that IL-IO has biological effects on hematopoietic progenitor cells, and (3) that IL-IO regulates the expression of the Bcl-2 protein in primary human hematopoietic progenitor cells.
MATERIALS AND METHODS

Cells.
Normal human BM was aspirated after informed consent from healthy donors of the allogeneic BM transplantation program. Peripheral blood (PB) mononuclear cells were obtained after informed consent from leukapheresis of healthy donors on G-CSF treatment for allogeneic transplantation. Cells were diluted with phosphate-buffered saline (PBS), pH 7.5, and layered on Ficoll-Hypaque (Pharmacia LKB Biotechnology Inc, Piscataway, NJ). Low density mononuclear cells were isolated from the interphase after gradient centrifugation for 35 minutes at 2,500 rpm. Cells were washed twice in PBS and resuspended in PBS supplemented with 1% bovine serum albumin (BSA). CD34' cells were obtained by positive selection using the CellPro Ceprate LC system according to the manufacturer's instructions (CellPro, Bothell, WA). Briefly, 2 X IOx unseparated human BM cells or PB cells were incubated with biotinylated mouse-antihuman CD34' monoclonal antibodies (MoAbs) for 25 minutes at 4°C. cells were washed with ice cold PBS and CD34' cells were isolated using a streptavidin-biotin affinity column. CD34' cells were recovered from the column and resuspended in RPMI supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin, 100 pg/mL streptomycin, and 3 mg/ml glutamine. Cellular enrichment was assessed by flow cytometry using CD34specific MoAb linked to phycoerythrin (Becton Dickinson, Mountain View, CA), and purity of CD34' cells was >90%.
Human Bcl-2 specific mouse MoAb was obtained from DAKO GmbH (Hamburg, Germany). Sheepantimouse specific horseradish-peroxidase-conjugated polyclonal antisera and fluorescein (FITC) conjugated goat-antimouse polyclonal antisera were purchased from Amersham Corp (Arlington Heights, IL). Purified recombinant human IL-4, IFN-y, IL-la, IL-6, SCF, IL-3, IL-IO, and GM-SCF were purchased from Genzyme (Cambridge, MA).
Oligonucleotides Bcl-2 antisense oligonucleotides substantially decrease the survival of CD34' hematopoietic progenitor cells in vitro and IL-10 is a potent inhibitor of Bcl-2 antisense induced cell death. CD34' hematopoietic progenitor cells were plated in 96-well cell culture plates in medium alone (panel 11, in the presence of 20 ng/mL of rhlL-10 (panel 2). in the presence of 25 pmol/L Bcl-2 antisense or sense oligonucleotides (panels 3 and 4, respectively) or in the presence of a combination of Bcl-2 antisense or sense and IL-10 (panels 5 and 6, respectively). Cell viability was assessed by light microscopy after 20 hours of culture. base composition like the antisense oligonucleotide (5'-GCCACC-CGCGGCCATCCTT-3') were used. All oligonucleotides were purchased from Birsner & Grob-Biotech GmbH (Freiburg. Germany). Oligonucleotides were purified by high-pressure liquid chromatography (HPLC) and concentration was adjusted to 500 pmoVL in 10 mmol/L Tris, pH 7.5 and I mmol/L EDTA and oligonucleotides were stored at -20°C. Amplification of cDNA by polymerase chain reaction (PCR) was performed using the following sense and antisense primers: Bcl-2 sense S-CGACGACTTCTCCCGCCGCTA-CCGC-3', Bcl-2 antisense 5'-CCGCATGCTGGGGCCGTACAG-TTCC-3'. Bcl-2 cDNA amplification was compared to the amplification of the ubiquitously expressed housekeeping porphobilinogen deaminase gene (PBGD): PBGD sense S'-TCTCTGGTA-ACGGCAATGCGGCTGCAAC-3'. PBGD antisense 5'-TCAATG-
7TGCCACCACACTGTCCGTCTT-3'.''
CD34' cells were resuspended in RPMI without FCS at a cellular density of 5 x IO4 cells/mL or 10' cells/ mL. Primary human CD34' cells were seeded in 96-well plates at 100 pL per well and stimulated with different combinations of IL-4 (100 ng/mL). IFN-y (100 UlmL), IL-la (100 U/mL), IL-6 ( I 0 0 So3 agar colony assav.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From ng/mL), SCF (100 U/mL), IL-3 (100 U/mL), and IL-IO (100 ng/mL or as mentioned) in the presence or absence of Bcl-2 antisense, sense or nonsense oligonucleotides. Oligonucleotides were used at concentrations ranging from SO pnovL to 0 pmol/L. Cells were incubated without serum in the presence or absence of the oligonucleotides for 4 to 5 hours. FCS was then added to a final concentration of 10% and cultures were incubated overnight for 16 to 20 hours at 3 7 T , 5% COz. Two thousand viable cells (or as mentioned in the text) were finally resuspended in 1 mL of plating mixture of 0.8% methylcellulose (WAK Chemie, Bad Homburg, Germany), 30% Iscove's modified Dulbecco's medium (GIBCO Life Technologies, Paisley, Scotland), 20% FCS (PanSystems, Aidenbach, Germany), and 10% BSA (Boehringer Mannheim, Germany) supplemented with 40 ng/mL GM-CSF. Cells were plated in 35-mm petri dishes (Miles Scientific, IL) and plates were incubated in a humidified atmosphere at 3 7 T , 5% C 0 2 . Colonies containing >SO cells were scored on day 14. All experiments were performed in triplicate.
Five-hundred thousand CD34' cells were seeded in 500 pL of RPMI without FCS in a 24-well plate and treated with either sense or antisense oligonucleotides (25 pmol/L) in the presence or absence of 20 n g h L recombinant human IL-IO. FCS was added to the cultures to a final of 10% after an incubation time of 5 hours and cells were incubated at 37"C, 5% COz overnight for 16 to 20 hours. Cells were obtained by centrifugation and cell lysis was performed in 25 pL of cell lysis buffer (100 mmol/L Tris [pH 7.51, 57 mmol/L NaCI, 1% Triton X-100 [Sigma, St Louis, MO], 1% phenylmethylsulfonyl fluoride, and 1% aprotinin) as described." The suspension was incubated on ice for 30 minutes and nuclei were cleared by centrifugation at 10,000 rpm for 10 minutes at 4°C. Supernatants were transferred to new tubes and protein concentration was determined. Fifty micrograms of the whole cell lysates were resolved by electrophoresis on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After transfer to nitrocellulose equal loading was controlled by staining the membranes with Poinceau-Red in 3% trichloric acid (Sigma)." Blots were blocked with 2% BSA in TBST (SO mmol/L Tris-HC1, pH 7.5; 150 mmol/L NaC1; 0.5% Tween-20) and probed with mouseantihuman Bcl-2 specific MoAb at 1:1,000 in TBST for 1 hour at room temperature. Blots were washed for 30 minutes in TBST and incubated with a secondary sheep-antimouse-HRF'T conjugated antibody 1:4,000 in TBST for 30 minutes at RT. Blots were washed and protein bands were detected using the ECL system (Amersham
RNA extraction and reverse transcribed-PCR (RT-PCR) analysis.
RNA was extracted from 5 X lo5 cells by the acid guanidiniurd phenol/chloroform method.' Two micrograms of each RNA was RT by using M-MuLV reverse transcriptase (Boehringer Mannheim)
Western blor analyses.
COP). and 20 nmol dATP/dTTP/dCTP/dGTP, 25 U RNase Inhibitor (Boehringer Mannheim) in the presence of 40 mAzh0 u of primer dT6 (Boehringer Mannheim) in a total of 20 pL. Four microliters of the cDNA pool were amplified by PCR with the use of the Bcl-2 primers mentioned above that span a 318-bp human Bcl-2 sequence. cDNA was amplified in a SO pL vol with 2 U of Taq polymerase (Perkin-Elmer Cetus, Nonvalk, CT), 20 pmol/L of the hu-Bcl-2 or PBGD specific primers, respectively, and 100 mmol/L each of dATP, dCTP, dlTP, and dGTP. Amplification was achieved using a 30 cycle reaction program of 1 minute 94, 1 minute 72°C'7,3". PCR products were analyzed by electrophoresis on a 1% agarose gel and visualized by staining with ethidium bromide.
Cells were incubated an adhesive slides (Bio-Rad Laboratories, Hercules, CA). Cells were fixed and permeabilized with 2% paraformaldehyde and 0.1% Saponin. Anti-hBcl-2 MoAb (1: 100 in PBS) and FITC-conjugated goat-antimouse antisera (1500 in PBS) were used. Photomicrographs were taken using a Zeiss laser confocal microscope (Zeiss, Jena, Germany).
Confocal microscopy.
RESULTS
Bcl-2 antisense decreases the survival of CD34+ hematopoietic progenitor cells and inhibits colony-forming unitgranulocyte macrophage (CFU-GM) dependent colony
growth. To study the biological role of the Bcl-2 gene expression in hematopoietic progenitor cells primary human CD34' cells were isolated from BM or PB of healthy donors by immunoaffinity chromatography to 90% purity. CD34' cells were incubated with 25 pmoVL of Bcl-2 specific antisense or sense oligonucleotides in vitro and cell survival was determined by light microscopy (Fig 1, panels 1 and 3) . After a 20 hours incubation period cell survival was significantly reduced in cultures that were treated with Bcl-2 antisense compared to cells in untreated or Bcl-2 sense treated cultures (Fig 1, panels 1, 3, and 4) . In contrast, Bcl-2 antisense did not effect cell survival in DG75 cells that do not express detectable levels of the Bcl-2 protein (data not shown). To further study the impact of Bcl-2 expression on the outgrowth of myeloid colonies in vitro, 2,000 viable CD34+ cells as determined by trypan blue exclusion, were plated in a methylcellulose colony assay employing 40 ng/mL of recombinant human GM-CSF. After 14 days of culture GM-CFC colony growth was determined. Under basic culture conditions 0.65% to 4% of the cells seeded had formed mixed myeloid colonies (Table 1) . No difference in colony forming potential was noted when freshly isolated CD34' cells or cells cultured for 20 hours were used (data not shown). Interestingly, Bcl-2 specific antisense ablated the GM-CSF dependent colony growth at a final concentration of 25 pmol/L (Table I , Fig 2A) . Dose titration studies revealed that the addition of 12 to 18 pmol/L of the Bcl-2 antisense oligonucleotides was sufficient to inhibit 50% of the CFU-GM colony forming potential ( Fig 2B) . To control for the specificity of the Bcl-2 antisense effects and to determine non specific side effects induced by the phosphorothioate oligonucleotides the following experiments were performed. Equal amounts of Bcl-2 sense or nonsense oligonucleotides were added to the in vitro cultures and outgrowth of CFU-GM was determined. Equal amounts of sense or nonsense oligonucleotides did not substantially decrease the outgrowth of CFU-GM colonies from primary human CD34' cells compared to control cultures without phosphorothioate-oligonucleotides (Table 1 ). Thus. these results suggested that the Bcl-2 antisense used in these experiments effected the outgrowth of mixed myeloid colonies in a specific manner. Furthermore, these data implied that Bcl-2 gene expression is necessary for the outgrowth of mixed myeloid colonies from primary CD34' human hematopoietic progenitor cells in vitro. IL-10 reverses the Bcl-2 nntisetise specific itikihitiori of CFU-GM colony growth. In an attempt to further modulate BcI-2 expression in human CD34' cells the following experiments were performed. Regulation of the Bcl-2 protein in various cell types has been demonstrated by many cytokines. Thus, initial experiments were performed with the use of IL-3, IL-6, IL-4, IL-6, IFN-y, IL-la. or IL-IO in the presence or absence of Bcl-2 antisense or sense, respectively. Cells were preincubated with individual cytokines and the BcI-2 specific nuclcotides for 20 hours and subsequently plated to test for the outgrowth of GM-CSF dependent colonies. Figure 3 shows that early acting cytokines like SCF were able to increase total colony numbers in vitro but were not sufficient to reverse the Bcl-2 antisense induced growth inhibition. In these experiments we found that IL-3, IL-6. and IL-10 were capable of partially or almost completely reversing the growth inhibiting effects of Bcl-2 antisense on myeloid progenitor cells (Fig 3) . The biological effect of IL-IO in restoring GM-CFC colony growth was most prominent and this observation prompted us to a more detailed study. To further determine IL-IO'S effects on the survival of primary human hematopoietic progenitor cells and to further study 
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IL-lo's effects on the outgrowth of GM-CSF dependent col-
onies from CD34' primary human hematopoietic progenitor cells, initial experiments were repeated in the presence of rhIL-IO. Thus, cell culture experiments and colony assays from IL-10 treated CD34' cells were performed in the presence or absence of Bcl-2 specific antisense, sense or nonsense oligonucleotides. Under basic overnight cell culture conditions of Bcl-2 antisense treated CD34' hematopoietic progenitor cells IL-10 was able to rescue cells from cell death and to maintain cell viability at basal levels (Fig 4,  panels 1, 2, 3, and 5) . No difference of cellular viability was observed in the cultures that were left untreated, treated with Bcl-2 sense or antisense in the presence of rhIL-10. However, when 2,000 viable CD34' progenitor cells were plated in the methylcellulose GM-CFU assay IL-10 did not induce an increase in the outgrowth of myeloid colonies when cells were preincubated with IL-10 alone for 20 hours (Fig 4A,  Table I) . In contrast, the addition of 100 ng/mL of recombinant human IL-IO was sufficient to reverse the otherwise complete growth inhibitory effects of 25 pmoVL of Bcl-2 specific antisense oligonucleotides (Table 1, Fig 4A) . Thus, IL-10 appeared to counteract the inhibition of the formation of mixed myeloid colonies from hematopoietic progenitor cells induced by Bcl-2 specific antisense ( Table 1 ). We controlled for the IL-10 specificity of this effect by the following sets of experiments. First, Bcl-2 sense and nonsense oligonucleotides were added to the L -I O treated cultures and second, dilution experiments were performed adding the recombinant human IL-10 in concentrations from 500 ng/mL to 0.8 ng/mL to the cultures. The short-term addition of IL-IO to Bcl-2 sense or nonsense treated CD34' human cells did not alter the outgrowth of GM-CSF driven colonies compared to the colony forming potential of non-treated cells. Second, 4 to 20 ng/mL of recombinant human IL-IO was sufficient to reverse the growth inhibitory affects of a final concentration of 25 pnoVL Bcl-2 antisense oligonucleotides ( Fig 4B) . Thus, these results indicate that human IL-IO can reverse the growth inhibitory effects of Bcl-2 antisense on CD34' hematopoietic progenitor cells. These results further indicate that IL-IO might be a probable candidate cytokine to rescue progenitor cells from programmed cell death by the modulation of the Bcl-2 gene expression in primary hematopoietic progenitor cells. IL-10 increases the expression of the Bcl-2 protein in CD34' cells. To further study the mechanism by which IL-I O reversed the Bcl-2 antisense driven inhibitory effects on the outgrowth of mixed myeloid colonies in vitro Western blot experiments were performed to determine the expression of the Bcl-2 protein in CD34' cells. Five-hundred thousand CD34' were lysed directly after cell harvest or after a 20hour cell culture period, protein concentration was adjusted to 50 pg per lane, proteins were separated on 12% SDS-PAGE and Western blots were probed with Bcl-2 specific MoAb (Fig 5) . Pretreatment of CD34' cells with 25 pmoV L Bcl-2 antisense oligonucleotides decreased the expression of the Bcl-2 protein in these cells whereas BcI-2 sense oligonucleotides did not affect the Bcl-2 expression ( Fig 5) . Most interestingly, the addition of 20 ng/mL of recombinant human IL-IO to the Bcl-2 antisense treated cultures of hemato- poietic progenitor cells restored basal Bcl-2 protein levels in these cells ( Fig 5) . Moreover, pretreatment of the CD34' cells with 20 ng/mL of recombinant human IL-IO for 20 hours increased the basal expression of Bcl-2 as detected by Westem blot analysis. To further control for the IL-IO dependent regulation of basal Bcl-2 expression in CD34' hematopoietic progenitor cells, Bcl-2 levels were studied by immunofluorescence in untreated and IL-IO treated cells. CD34' cells that were either used directly after the CD34' immunoaffinity isolation procedure or kept in culture for 20 hours displayed low but detectable amounts of the Bcl-2 protein in their cytoplasm (Fig 6) . In contrast, under the influence of IL-IO most progenitor cells (>70%) expressed the Bcl-2 protein at elevated levels. These data show that IL-IO elevates basal expression of the Bcl-2 protein in CD34' hematopoietic progenitor cells.
IL-IO transcriptionally regulates Bcl-2 expression in human hematopoietic progenitor cells.
To further assess whether the IL-IO induced upregulation of the Bcl-2 protein expression correlated with the increased transcription of the Bcl-2 message, a parallel series of experiments was performed. Total cellular RNA was extracted from CD34' human hematopoietic progenitor cells that were either left untreated or treated with recombinant human IL-IO for 20 hours. Bcl-2 specific mRNA transcripts were amplified by RT-PCR. An access of the predicted BcI-2 specific mRNA was present in IL-10 treated cells compared to the Bcl-2 transcript amplified from untreated CD34' cells (Fig 7, lanes  1 and 4) . To further validate this observation, three additional control experiments were performed. First, amplification of .."_.. 0
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Bcl-2 transcripts was performed in parallel to the amplification of the ubiquitously expressed mRNA of the housekeeping gene PBGD. Second, threefold dilution series of the reverse transcribed cDNA were performed before amplification by PCR and overexpression of Bcl-2 mRNA on IL-I O treatment of the cells was shown compared to Bcl-2 mRNA levels in untreated cells (Fig 7) . Third, to control for the presence of genomic DNA in the RNA preparations, we conducted PCR analysis in the absence of the reverse transcription step. In these experiments no PCR products were observed thus indicating a lack of genomic DNA in the RNA preparations (data not shown). In summary, these results thus show that IL-IO treatment increases Bcl-2 mRNA expression in human CD34' hematopoietic progenitor cells leading to an increased expression of the Bcl-2 protein in these cells. .
IL-I O sustains the colonyfortning potentinl of myeloid precursor cells in vitro. Primary CD34' hematopoietic
progenitor cells were cultured at Io" cells per mL in the presence or absence of rhIL-10 for up to 15 days. 1L-IO was added at a concentration of initially 20 ng/mL on day 0, followed by subsequent IL-IO additions of 5 ng/mL every other day. GM-CSF driven colony growth was determined in the methylcellulose assay. When cells were harvested within the first 4 days of in vitro culture no differences were observed in the outgrowth of myeloid colonies regardless of IL-IO pretreatment of the CD34' cells. Upon prolonged culture of the human CD34' cells under basic culture conditions cell viability (data not shown) as well as colony forming potential significantly dropped in the untreated progenitor cells (Fig 8) . In contrast, the addition of rhlL-IO to these cultures could maintain the subsequent outgrowth of myeloid colonies for more than 2 weeks. Thus, these data indicate that IL-IO has the potential to increase the ratio of hematopoietic progenitor cells that survive growth factor starvation in vitro. 
DISCUSSION
The Bcl-2 intracellular protein promotes cell survival and expression of Bcl-2 occurs in many normal as well as malignant cell types.' Bcl-2 is expressed in immature proliferating cells as well as in long-lived postmitotic cells.' Hematopoietic progenitor cells express Bcl-2 during early stages of hematopoiesis whereas Bcl-2 expression is downregulated on cellular differentiation.' Recent data by Park et a13' provide evidence that Bcl-2 expression occurs primarily in a blast CD34' subpopulation whereas more immature small quiescent CD34' cells are negative in Bcl-2 expression. The later cell population relies on the functionally homologous protein Bcl-XL for survival. Data presented here indicate the importance of Bcl-2 expression for the formation of mixed myeloid colonies from primary human hematopoietic progenitor cells. Using a GM-CFC colony assay we studied the effects a blockade of Bcl-2 expression would have on the growth of committed myeloid progenitor cells. The data presented in this study demonstrate the growth inhibitory effect of Bcl-2 antisense on hematopoietic progenitor cells in vitro. Moreover using equal numbers of viable cells in the colony assay Bcl-2 antisense almost completely inhibited the outgrowth of myeloid GM-CSF dependent cells. Thus, a poten-tial role of Bcl-2 in proliferating blastic hematopoietic progenitors is the maintenance of the clonogenic potential in these cells. Evidence for this hypothesis was further supported by two reports. First, the stable transfection and overexpression of Bcl-2 in murine FDCPmix multipotent hematopoietic progenitor cells lead to an increased colony forming potential in these cells."' Second, on long-term exposure of cells to Bcl-2 antisense overall cell death and ablation of cell proliferation has been reported in primary human CD34' progenitors."." These effects were described by Campos et al" when 50 pmoVL of Bcl-2 antisense were added on day 0 followed by a second addition of BcI-2 antisense on day 6. In our experiments lower doses of 25 pmol/L to 12 pmol/ L of BcI-2 antisense substantially decreased the outgrowth of myeloid colonies even when cells were pretreated for 16 to 20 hours. Under the conditions used BcI-2 specific antisense nucleotides substantially decreased cellular survival and blocked the GM-CSF dependent colony formation of human CD34' cells in a concentration dependent manner. Sense or nonsense oligonucleotides did not effect the formation of myeloid colonies at equimolar concentrations in the established in vitro system. This functional observation was supported by expression data of the BcI-2 protein. In addition to blocking the colony forming potential in human CD34' cells, Bcl-2 antisense oligonucleotides decreased the level of Bcl-2 protein expression in these cells. Thus, decreased Bcl-2 expression levels as determined by morphology coincided with the functionally decreased colony forming potential in human hematopoietic progenitor cells upon treatment with Bcl-2 antisense. Thus, expression of BcI-2 in CD34' cells that undergo differentiation appears to be important for the maintenance of the colony forming potential.
Biologic effects of multiple cytokines like IL-3 or GM-CSF on the expression of the Bcl-2 protein are de~cribed.~ However, considerable uncertainty remains concerning the functional role of IL-10 for the differentiation of hematopoietic cells. IL-IO which has been identified as an immunomodulatory cytokine is mainly produced by activated B and T lymphocytes as well as macrophages but is also found in the BM of healthy individuals.32 IL-lo's antiinflammatory functions are well-defined and IL-10 has been shown to inhibit the production of proinflammatory cytokines and radicals in macrophages and lymphocytes that express IL-10 receptors in low Some indirect biological effects of IL-10 on hematopoietic cells have been described in the murine ~ystem.'".'~ In vitro, IL-10 was found to synergize with SCF, IL-3, and IL-4 to drive mast cell growth.35 IL-10 has been shown to inhibit IL-7 mediated B-cell g r~w t h .~~.~~ However, uncertainty still remains whether IL-10 can directly influence the formation of myeloid colonies from human hematopoietic progenitor cells and no data exist so far that would explain a functional role of IL-10 expression in human BM. The observation made herein shows that human CD34' progenitor cells have the potential to respond to IL-10. In splenic B lymphocytes cell survival is increased in the presence of IL-10 cultures.36
The mechanism underlying this phenomenon in splenocytes is the upregulation of Bcl-2 protein levels in B lymphocytes on exposure to IL-IO.." Taken together these results prompted us to investigate IL-lo's role on the formation of the GM-CSF dependent outgrowth of myeloid colonies in vitro. It is of interest that in the system used baseline levels of GM-CSF driven growth of myeloid colonies were left unaltered by IL-10 on short-term treatment of the cells but long-term colony-forming potential was increased upon IL-10 exposure of the hematopoietic progenitor cells. IL-10 appeared to function as a regulatory molecule which induced the expression of the Bcl-2 protein in hematopoietic progenitor cells. IL-10 directly upregulated the expression of basal Bcl-2 protein expression levels in CD34' cells compared to levels of Bcl-2 that are found in freshly isolated CD34' cells. Data presented in this study indicate that IL-10 dependent induction of Bcl-2 occurs at a transcriptional level because Bcl-2 specific mRNA is upregulated upon IL-10 treatment of CD34' cells. One possible explanation for the regulation of BcI-2 expression could be the presence of a positive regulatory IL-10 responsive element in the promoter of the Bcl-2 gene. Primary results obtained by gel shift analyses so far employing specific oligonucleotide probes indicated such an IL-10 response element in the Bcl-2 promoter region (R.M. Weber-Nordt and J. Wehinger, unpublished results). These results suggest an important role of IL-10 in the regulation of Bcl-2 expression in early stages of hematopoiesis. In addition, cellular Bcl-2 expression levels that were downregu-lated on exposure to Bcl-2 antisense oligonucleotides could be elevated to normal expression levels on exposure of the CD34+ cells to IL-10. Two possible molecular mechanisms could account for this IL-10 dependent effect. Phosphorothioate modified oligonucleotides are known to mediate their inhibitory effects by an RNase-H mediated mechanism.37 Thus, IL-10 could have inhibitory effects on the RNase activity in hematopoietic progenitor cells thus leading to a reduced effect of the antisense oligonucleotides. The effect of IL-10 on RNase-H expression and activity is currently unknown but current work is in progress to investigate this hypothesis. Second, IL-10 could neutralize the inhibitory action of Bcl-2 antisense by increasing the mass of Bcl-2 transcripts in the cells. Because IL-10 increases the expression of Bcl-2 in untreated human hematopoietic progenitor cells under basal cell culture conditions, our current data on Bcl-2 mRNA and protein levels favor the latter hypothesis. Thus, the current study extends the functional importance of IL-IO and makes the novel point that IL-10 may function to increase Bcl-2 expression in hematopoietic progenitor cells. Members of the Bcl-2 family of proteins form heterodimeric complexes with other family members. Formation of heterodimers between death promoting and death repressing proteins appears to be essential for death repressor functions.' Thus, studies are underway to further define IL-lo's role in the regulation of other proteins that are involved in the process of programmed cell death like Bax, Bcl-X, Bag, Bak, and p53. IL-10 which can be detected in low levels in normal BM appears an important link between the immune system and the hematopoietic system. This study provides evidence for IL-lo's life promoting role in the apoptotic processes involved in the early maturation of hematopoietic progenitor cells. The expression of IL-10 in normal BM may be necessary to keep the balance of cell death and cell survival on the side of cell survival in early hematopoiesis.
